Study by blood doctors a breakthrough for hemophiliacs

(University of the Witwatersrand) The HAVEN 3 study found that a new type of protein, emicizumab (trade name: Hemlibra), can be administered subcutaneously, rather than intravenously, and that it does not cause an immune response which prevents blood from clotting.
Source: EurekAlert! - Medicine and Health - Category: International Medicine & Public Health Source Type: news